ARTV

Business Context and Reporting Period

Company: Artiva Biotherapeutics, Inc. (ARTV)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: Artiva is a clinical-stage biotechnology company developing off-the-shelf, allogeneic natural killer (NK) cell-based therapies for autoimmune diseases. The company has no products approved for commercial sale and has incurred net losses since inception. Its lead product candidate, AlloNK (AB-101), is in clinical development for refractory rheumatoid arthritis (RA) and other B-cell driven autoimmune diseases.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by $3.2 million (16%) to $23.5 million, driven primarily by a $2.3 million increase in operating expenses.
• R&D Expenses: R&D expenses rose by $2.3 million to $19.3 million. This increase was primarily due to higher external costs associated with the development and ongoing clinical trials of AlloNK in autoimmune diseases.
• Interest Income Decline: Interest income decreased by $0.9 million to $0.9 million, attributed to lower investment balances compared to the prior year.
• Liquidity Position: Total cash, cash equivalents, and short-term investments decreased by approximately $21.2 million to $86.8 million, reflecting operating cash burn partially offset by investment maturities.
• Stock-Based Compensation: Total stock-based compensation expense decreased by $0.5 million to $1.6 million.

Guidance, Outlook, and Management Commentary

• Clinical Progress: Management announced positive initial clinical data for AlloNK in combination with rituximab. As of April 3, 2026, over 70 autoimmune patients had initiated treatment. In refractory RA, more than 50% of patients with six months of follow-up achieved an ACR50 response.
• Regulatory Alignment: The company has aligned with the FDA on a single registrational randomized controlled trial design for AlloNK in refractory RA. The trial is expected to enroll approximately 150 patients, with initiation planned for the second half of 2026 and primary efficacy data expected in the second half of 2028.
• Liquidity Outlook: Management believes existing cash, cash equivalents, and investments ($86.8 million) are sufficient to fund planned operations into the second quarter of 2027. The company expects to continue incurring significant losses for the foreseeable future and will require substantial additional funding to complete development and commercialization.
• Risks: Key risks include the unproven nature of NK cell therapies for autoimmune diseases, dependence on the success of AlloNK, potential manufacturing delays, and the need for future capital raises which may cause dilution.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $86.8 million cash balance to fund operations through Q2 2027 given the current burn rate of ~$21 million per quarter.
• Clinical Data Validation: Review the full clinical dataset for the 21 refractory RA patients and 11 Sjögren's disease patients to confirm the reported ACR50 response rates and safety profile (specifically regarding cytokine release syndrome and infections).
• Manufacturing Capacity: Assess the status of the company's own clinical manufacturing facility in San Diego and reliance on third-party partner GC Cell for commercial scale production.
• Capital Requirements: Evaluate the potential dilution impact of future financing needs required to support the planned Phase 3 trial and commercialization efforts.
• Intellectual Property: Confirm the status of patent protection and license agreements with GC Cell, particularly regarding the core NK cell technology and territorial rights.